

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED

AUG 02 2001

File Information Unit

In re Application of

Application Number

Filed

08/853803

May 9, 97

Group Art Unit

Examiner

Paper No. #7

Assistant Commissioner for Patents
 Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- ___ (A) referred to in United States Patent Number 6037368 column ___
- ___ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____ on page _____ of paper number _____
- ___ (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____, or
- ___ (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Virginia Click

Signature

Aug 2, 01

Date

VIRGINIA Click

Typed or printed name

FOR PTO USE ONLY

Approved by: 

(Initials)

Unit: 



US006037368A

United States Patent [19]

Podos et al.

[11] **Patent Number:** 6,037,368[45] **Date of Patent:** Mar. 14, 2000[54] **8-ISO- PROSTAGLANDINS FOR GLAUCOMA THERAPY**[75] **Inventors:** Steven M. Podos, Tenafly, N.J.;
Thomas W. Mittag, Pleasantville, N.Y.;
Bernard Becker, University City, Mo.[73] **Assignee:** Mount Sinai School of Medicine, New York, N.Y.[21] **Appl. No.:** 09/073,552[22] **Filed:** May 6, 1998**Related U.S. Application Data**

[63] Continuation of application No. 08/853,803, May 9, 1997, abandoned.

[51] **Int. Cl.⁷** A61K 31/215; A61K 31/19[52] **U.S. Cl.** 514/530; 514/573; 514/913[58] **Field of Search** 514/530, 573,
514/913[56] **References Cited****U.S. PATENT DOCUMENTS**4,132,847 1/1979 Kuhla et al. .
4,599,353 7/1986 Bito .
5,151,444 9/1992 Ueno et al. .
5,173,507 12/1992 DeSantis et al. .5,208,256 5/1993 Ueno .
5,262,437 11/1993 Chan .
5,462,968 10/1995 Woodward .
5,476,872 12/1995 Garst et al. .
5,565,492 10/1996 DeSantis et al. .
5,578,618 11/1996 Stjernschantz .
5,631,287 5/1997 Schneider 514/530**FOREIGN PATENT DOCUMENTS**

9411002 5/1994 WIPO .

OTHER PUBLICATIONS

Podos et al., Mar. 15, 1998, Invest. Ophthalmol. Visual Sci. 39(4):S258, abstract 1178-B57 (title on the Internet several months earlier, believed to be in 1998).

Wang et al., Mar. 15, 1997, Invest. Ophthalmol. Visual Sci. 38(4):S815, abstract 3795-B396.

Primary Examiner—Zohreh Fay*Attorney, Agent, or Firm*—Bakerbotts LLP[57] **ABSTRACT**

The present invention relates to the use of 8-iso prostaglandins and their derivatives for decreasing intraocular pressure, for example in the treatment of glaucoma. It is based, at least in part, on the discovery that 8-iso prostaglandin E₂ effectively decreased intraocular pressure by a trabecular meshwork outflow mechanism.

21 Claims, No Drawings